Sleijfer D T, Meijer S, Mulder N H
Pharm Weekbl Sci. 1985 Dec 13;7(6):237-44. doi: 10.1007/BF01959196.
In reviewing the literature about the clinical application of cis-diamminedichloroplatinum(II) (cisplatin) it can be concluded that the availability of cisplatin has been an important advance in cancer chemotherapy; especially in patients with disseminated testicular carcinoma and ovarian cancer cisplatin-based combinations are the first choice treatment. Our own investigations of the nature of the main form of toxicity of cisplatin, the nephrotoxicity, are mentioned and methods of its prevention are summarized.